Vo Manh-Cuong, Jung Sung-Hoon, Nguyen Van-Tan, Tran Van-Dinh-Huan, Ruzimurodov Nodirjon, Kim Sang Ki, Nguyen Xuan-Hung, Kim Mihee, Song Ga-Young, Ahn Seo-Yeon, Ahn Jae-Sook, Yang Deok-Hwan, Kim Hyeoung-Joon, Lee Je-Jung
Institute of Research and Development, Duy Tan University, Danang, Viet Nam.
Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.
Heliyon. 2024 Mar 13;10(6):e27892. doi: 10.1016/j.heliyon.2024.e27892. eCollection 2024 Mar 30.
Despite major advances in therapeutic platforms, most patients with multiple myeloma (MM) eventually relapse and succumb to the disease. Among the novel therapeutic options developed over the past decade, genetically engineered T cells have a great deal of potential. Cellular immunotherapies, including chimeric antigen receptor (CAR) T cells, are rapidly becoming an effective therapeutic modality for MM. Marrow-infiltrating lymphocytes (MILs) derived from the bone marrow of patients with MM are a novel source of T cells for adoptive T-cell therapy, which robustly and specifically target myeloma cells. In this review, we examine the recent innovations in cellular immunotherapies, including the use of dendritic cells, and cellular tools based on MILs, natural killer (NK) cells, and CAR T cells, which hold promise for improving the efficacy and/or reducing the toxicity of treatment in patients with MM.
尽管治疗平台取得了重大进展，但大多数多发性骨髓瘤（MM）患者最终仍会复发并死于该疾病。在过去十年开发的新型治疗选择中，基因工程改造的T细胞具有很大的潜力。包括嵌合抗原受体（CAR）T细胞在内的细胞免疫疗法正迅速成为MM的一种有效治疗方式。源自MM患者骨髓的骨髓浸润淋巴细胞（MILs）是过继性T细胞疗法中T细胞的一种新来源，其能有力且特异性地靶向骨髓瘤细胞。在本综述中，我们探讨了细胞免疫疗法的最新创新，包括树突状细胞的应用，以及基于MILs、自然杀伤（NK）细胞和CAR T细胞的细胞工具，这些有望提高MM患者治疗的疗效和/或降低治疗毒性。
